Medical Ultrasound Imaging
Saturday, 23 November 2024
 Info Sheets  Out- side     | 'Lantheus Medical Imaging, ' Searchterm 'Lantheus Medical Imaging,' found in 3 articles 1 definition [ • ] - 2 booleans [• ]Result Pages : • 
Lantheus Medical Imaging, Inc. engages in discovering, developing, and marketing medical imaging agents. Lantheus Medical Imaging has headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia. During its history, the company launched the products Cardiolite (Technetium Tc99m Sestamibi Preparation Kit), which has become the gold standard for use in myocardial perfusion imaging, and Definity (perflutren lipid microsphere) for use in suboptimal echocardiograms.From 2001 to 2008 Lantheus was part of the Bristol-Myers Squibb Medical Imaging, Inc. group. Ultrasound Contrast Agents:
Contact Information
MAIL
Lantheus Medical Imaging
Bldg. 200-2 331 Treble Cove Rd. N. Billerica, MA 01862 USA
ONLINE
CONTACT
• 
Bristol-Myers Squibb Medical Imaging, Inc. was a wholly-owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), a pharmaceutical and related health care products company. Bristol-Myers Squibb sold its medical imaging business in 2007 to the private equity firm Avista Capital Partners for $525 million, as part of its effort to focus on its core pharmaceutical pipeline.Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging and later evolved through its transition from NEN to DuPont, followed by Bristol-Myers Squibb Medical Imaging (BMS), and finally named Lantheus Medical Imaging. • 
From Lantheus Medical Imaging.Activated DEFINITY® Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. Echocardiography with Definity produced more detailed images of the heart in difficult-to-image patients versus echocardiography alone, and images obtained with the contrast agent provided a more accurate assessment of segmental wall motion compared with unenhanced images. See also Coherent Contrast Imaging. In August 2001 DuPont Pharmaceuticals Company received FDA approval.
Drug Information and Specification
RESEARCH NAME
DMP 115, MRX 115
INDICATION -
DEVELOPMENT STAGE APPLICATION
Intravenous
TYPE
Lipids:DPPA, DPPC,MPEG5000 DPPE
CHARGE
Negative
Octafluoropropane
MICROBUBBLE SIZE
98% < 10μm
PRESENTATION
Package contains four 2mL clear glass single-use vials.
STORAGE
Refrigerate 2−8 °C
PREPARATION
Activate through Vialmix agitation
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
DISTRIBUTOR
North America, Australia, South Asia, Middle East
 Further Reading: Basics:
News & More:
Result Pages : | Share This Page     Look Ups |
Medical-Ultrasound-Imaging.com
former US-TIP.com
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology TIP • Medical-Ultrasound-Imaging
Copyright © 2008 - 2024 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertise With Us
former US-TIP.com
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology TIP • Medical-Ultrasound-Imaging
Copyright © 2008 - 2024 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertise With Us
[last update: 2023-11-06 01:42:00]